OncoMatch/Clinical Trials/NCT07172802
A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid Tumors
Is NCT07172802 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies GI-108 for advanced solid tumor.
Treatment: GI-108 — The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-108, as a single agent, in patients with advanced or metastatic solid tumors
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Tumor Agnostic
Non-Small Cell Lung Carcinoma
Head and Neck Squamous Cell Carcinoma
Pancreatic Cancer
Renal Cell Carcinoma
Disease stage
Metastatic disease required
Measurable disease as per RECIST v1.1.
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: immunotherapy related to mode of action of gi-102
Lab requirements
Blood counts
adequate organ and marrow function as defined in protocol
Kidney function
adequate organ and marrow function as defined in protocol
Liver function
adequate organ and marrow function as defined in protocol
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07172802 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior immunotherapy related to mode of action of gi-102 disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify